Dose group | Patient no. | Age (y) | Sex | Tumor type | Tumor size (CT axial dimensions) | Clinical staging | PD-L1 expression (%) | ECOG score |
Group 1 (3.8–8.4 MBq/kg, 1.2–2.1 μg/kg) | 1 | 49 | Male | Adenocarcinoma | 37 × 27 mm | cT4N3M1 IV | NA | 1 |
2 | 75 | Male | Squamous cell carcinoma | 44 × 48 mm | T3N3M1 IV | 20 | 1 | |
3 | 75 | Male | Squamous cell carcinoma | 55 × 46 mm | T2bN3M0 IIIB | 0 | 1 | |
Group 2 (9.1–10.4 MBq/kg, 5.6–6.1 μg/kg) | 4 | 65 | Male | Adenocarcinoma | 48 × 42 mm | T2bN3M1 IV | 0 | 0 |
5 | 57 | Male | Squamous cell carcinoma | 32 × 35 mm | cT2N2M0 IIIA | 55 | 0 | |
6 | 65 | Male | Squamous cell carcinoma | 30 × 58 mm | T2aN2M0 IIIA | 3 | 0 | |
Group 1 (3.8–8.4 MBq/kg, 1.2–2.1 μg/kg) | 7 | 75 | Female | Adenocarcinoma | 38 × 28 mm | T2aN0M0 | NA | 0 |
8 | 52 | Female | Squamous cell carcinoma | 33 × 23 mm | T2aN0M0 1B | 0 | 0 | |
9 | 36 | Female | Adenocarcinoma | 45 × 35 mm | T2aN2M1 IV | 1 | 1 | |
10 | 46 | Female | Adenocarcinoma | 42 × 35 mm | T3N1M0 IIIA | 50 | 0 | |
11 | 51 | Male | Squamous cell Carcinoma | 47 × 35 mm | T2aN3M0 IIIB | 2 | 0 | |
12 | 72 | Male | Adenocarcinoma | 46 × 53 mm | T2bN3M1 IV | NA | 1 | |
13 | 55 | Male | Squamous cell carcinoma | 71 × 78 mm | T4N0M1c IV | 85 | 0 | |
14 | 69 | Male | Squamous cell carcinoma | 20 × 28 mm | T3N1M0 IIIA | 10 | 0 | |
15 | 71 | Female | Squamous cell carcinoma | 78 × 95 mm | T4N1M1a IV | NA | 1 | |
16 | 60 | Male | Adenocarcinoma | 93 × 75 mm | T4N3M1a IV | 2 | 0 |
ECOG = Eastern Cooperative Oncology Group Performance Score; NA = not available.